Navigation Links
NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for Fiscal 2009
Date:11/5/2009

quarter of 2008.

Gross margin improved to 25 percent in the third quarter of 2009 as compared to 16 percent in the third quarter of 2008.

Net loss for the third quarter of 2009 was $10.0 million, or ($0.22) per share. This compares to a net loss of $15.0 million, or ($0.33) per share for the third quarter of 2008, which included the negative impact of a $1.8 million change in fair value of financial instruments.

Cash and cash equivalents as of September 30, 2009 were $22.1 million. The Company's cash usage for the third quarter of 2009 was $2.4 million.

For the third quarter of 2009, the Company had an Adjusted EBITDA loss of $2.4 million, adjusted for stock-based compensation, deferred revenue recognized and other non-recurring expenses, compared with an Adjusted EBITDA loss of $7.3 million in the third quarter of 2008. These results were better than the Company's guidance for an Adjusted EBITDA loss of $3.0 to $4.0 million for the third quarter of 2009. (See the exhibits for a reconciliation of this non-GAAP measure.)

Guidance:

For the fourth quarter of 2009, the Company is forecasting revenue to be between $37.0 to $39.0 million, a net loss in the range of $8.5 to $9.5 million or ($0.18) to ($0.21) per share, and an Adjusted EBITDA loss in the range of $1.5 to $2.5 million.

Supported by its strong performance year to date in 2009, the Company now anticipates revenue for the 2009 fiscal year to be in a range of $145 to $147 million, compared with its prior guidance for revenue to be in a range of $135 to $145 million.

This release contains a non-GAAP financial measure. A reconciliation of the Company's non-GAAP financial measure to its most comparable GAAP financial measure is in the exhibits to this press release.

Conference Call:

NxStage will also host a conference call today at 9:00 a.m. Eastern Time to discuss its third qua
'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
2. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
3. NxStage(R) to Report Third Quarter 2009 Financial Results
4. NxStage(R) Reports Significant Interim FREEDOM Study Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems ... the Australia Capsule Endoscopy Systems market. The report provides ... and average prices (in US dollars) within market segments: ... , Capsule Endoscopes , Capsule Endoscopy Data ... The report also provides company shares and distribution shares ...
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... Powers Lake, Wisconsin , announce that ... and co-marketing agreement allowing ScriptPro to bring TCGRx ... the United States . ScriptPro is ... workflow systems to retail and ambulatory pharmacies. TCGRx ...
(Date:7/25/2014)... , July 25, 2014 GrowBLOX Sciences, Inc. ... binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, an ... the acquisition of both cultivation and dispensary medical marijuana licenses ... to the MOU, GBLX will acquire a 20% equity interest ... proprietary GrowBLOX TM growing chambers, as well as all ...
Breaking Medicine Technology:Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) ... of Proellex(TM), an oral drug being developed to,relieve ... with Proellex results in a statistically highly,significant improvement ... well tolerated., Study Details and Results , This ...
... 03, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today ... Phase 2 trial of GVAX,immunotherapy for prostate ... in 80 patients with metastatic,hormone-refractory prostate cancer ... received the dose that is comparable to ...
Cached Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3
(Date:7/25/2014)... 2014 The Little Gym of Houston ... Sunday, July 27 at Discovery Green in downtown Houston. ... Katy, Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, ... , “We’re thrilled to be attending and performing at ... who owns the Sugarland-Missouri City location. “We believe in ...
(Date:7/25/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Ibuprofen and Oxcarbazepine Tablets . , The FDA ... one lot of Oxcarbazepine Tablets, by American Health Packaging (AHP), ... used for the treatment of certain types of seizures in ... recall is that Lot #142588, Expiration Date, 01/2016 of Ibuprofen ...
(Date:7/25/2014)... Ticket Down is a reliable ... in Berkeley at California Memorial Stadium. With the post-World ... football, the organizers of the 2014 Guinness International Champions Cup ... North America. With teams representing La Liga, English Premier League, ... of the best football players from around the world to ...
(Date:7/25/2014)... 2014 On July 22, 2014, ... client and the nation’s number one provider of ... announced their partnership with TransAct Merchant Solutions’ National ... ISO/MSP of Chase Paymentech Solutions, LLC, which provides ... Companies that are members of TransAct’s National Association ...
(Date:7/25/2014)... Hastings and Hastings, a personal injury ... to personal injury claims, announces free initial consultations. Hastings ... services for those that have been injured as a ... Free initial consultation services gives clients’ greater flexibility in ... personal injury claim . It also offers clients the ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
... A long-running Merck ad featured an older woman with this message: ... be?" and recommended that women ask their doctors about bone ... Merck's drug Fosamax. But this very drug, (generic name alendronate) turned ... the risk of hip fracture from 2 percent to 1 percent, ...
... the time of Chaucer were not dwarfs but only short ... was the case with women more or less, a new ... revealed. ,As part of their study, scientists researched ... upon Humber, North East Lincolnshire, and found that the average ...
... engineered adult stem cells from human umbilical cord blood to ... type 1 diabetes by allowing people to grow their own ... ,The study was conducted by a team of researchers led ... Branch at Galveston. ,As part of the study, ...
... has decided to send youths to learn meditation from Indian ... visit to the war-hit country Thursday with a trip ... the Art of Living Foundation, Iraqi Youth Minister Jasin Mohammed ... of Iraq to Bangalore to undergo the group's Youth Leadership ...
... Abdul Kalam Friday urge the nation's doctors to work for ... Post-Graduate Institute of Medical Sciences in Rohtak, Kalam called upon ... ,If each doctor showed the zeal to treat at ... lot of diseases could be taken care of. ...
... by the American Academy of Neurology finds conventionally recommended ... system Lyme disease. However, there is no compelling ... in treating symptoms that persist following standard therapy. The ... edition of Neurology, the scientific journal of the American ...
Cached Medicine News:Health News:Women Urged to Be Wary of Ads Promoting Unwanted Drugs 2Health News:Women Urged to Be Wary of Ads Promoting Unwanted Drugs 3Health News:Our Medieval Ancestors Were More or Less Similar to Us Than Previously Thought 2Health News:Art of Living Foundation to Train Iraqi Youths 2Health News:Antibiotics Highly Effective for Treating Lyme Disease 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Bausch & Lomb PreserVision® Soft Gel ... clinically proven Bausch & Lomb PreserVision® AREDS ... mg of FloraGlo Lutein., Lutein is a ... such as spinach. Lutein is highly concentrated ...
... a scientifically advanced multinutrient that ... and full body health. It ... including a diverse array of ... lycopene and OptiBerry and important ...
Medicine Products: